We present here the long-term results of three randomized clinical trials conducted on children with newly diagnosed acute lymphoblastic leukemia (ALL) between 1983 and 1998 by the Children Leukemia Cooperative Group (CLCG) from EORTC. In study 58831/32, the overall event-free survival (EFS) rates (± s.e.) at 6 and 10 years were 66% ± 1.8% and 65% ± 1.8%, respectively, and the risk of isolated central nervous system (CNS) relapse was 6% ± 1% and 7% ± 1%, respectively. In patients with a standard risk of relapse the omission of cyclophosphamide had no adverse effect on disease-free survival rates at 10 years (trial 58831). In medium-and high-risk patients the omission of radiotherapy did not increase the risk of CNS or systemic relapse (trial 58832). In study 58881 (1989-1998) the overall EFS rate at 8 years was 68.4% ± 1.2% and the risk of isolated CNS relapse was 4.2% ± 0.5%. In this trial which adressed three randomized questions, the following results were obtained: the combination of cytarabine at high doses with methotrexate at high doses during interval therapy did not improve prognosis. The addition of 6-mercaptopurine iv during maintenance increased the risk of late relapse. E. coli asparaginase was more toxic and has a higher efficacy than Erwinia asparaginase. Leukocyte counts Ͼ100 × 10 9 /l, specific genetic abnormalities, a poor initial response to steroids or a high level of minimal residual disease at early time points were consistently associated with an adverse prognosis in the 58881 trial.
Introduction
Since 1983, the Children Leukemia Cooperative Group (CLCG) from the EORTC has designed several ALL protocols. This group, initially composed of French and Belgium centers was joined by some Portuguese centers. Now 24 centers are participating in the ongoing trial. The high rate of success reported with the Berlin-Frankfurt-Munster (BFM) regimen prompted us to apply a similar structure to our studies. The main objectives for improvement of these already favorable results were (1) the decrease of immediate or late toxicity, at least in the low-risk group, by using less intensive regimens and (2) to improve efficacy by adding other cytostatic agents. Trial 58831 (1983) (1984) (1985) (1986) (1987) (1988) (1989) , designed to test the therapeutic contribution of cyclophosphamide in standard-risk patients, showed that the deletion of this alkylating agent, often used in consolidation, did not decrease the probability of maintaining complete remission. 1 CNS radiotherapy has been a component of BFM protocols, but its therapeutic value remained debatable, particularly bearing in mind its early and late detrimental effects. In trial 58832 (1983) (1984) (1985) (1986) (1987) (1988) (1989) , which encompassed high doses of methotrexate i.v., the omission of radiotherapy did not increase the risk of CNS or systemic relapse. 2 Thus, CNS radiotherapy was omitted in the subsequent trial 58881 (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) , which tested the possible efficacy of complementary CNS-directed chemotherapy. The combination of high doses of cytarabine with high doses of methotrexate during interval therapy did not improve the prognosis nor did the addition of intravenous 6-mercaptopurine during maintenance. [3] [4] [5] Between November 1990 and October 1993, a third question has been added to the 58881 protocol, in order to evaluate the efficacy and the toxicity of Erwinia asparaginase vs E. coli asparaginase. It was found that this agent plays a major role in the achievement and maintenance of complete remission. 6, 7 The long-term follow-up results of these three trials are presented below.
Materials and methods

Treatments
From 1983 to 1989, all children with ALL under 18 years of age were included in one of two studies: CLCG-EORTC 58831 study, for standard risk patients, and 58832, for medium and high risk patients. These trials were based on BFM-like protocols, in which the treatment stratification relied on three initial factors: the number of circulating blasts, the size of the liver and of the spleen below the costal margin. Risk factor (RF) calculation was carried out according to Langerman et al 8 (RF Leukemia = 0.2 × log 10 (blasts/mm 3 + 1) + 0.06 × cm hepatomegaly + 0.04 × cm splenomegaly). The protocol 58831 for standard risk ALL was designed for patients with a RF below 1.2, whereas medium (RF between 1.2-1.69) and high risk ALL patients (RF у1.7) were treated according to the more intensive protocol 58832.
For three trials (58831/32 and 58881) treatment started with 7 days of monotherapy with prednisone or prednisolone and one intrathecal (IT) dose of methotrexate. In trials 58831 and 58832, induction therapy (protocol IA) consisted of 4-weekly vincristine and daunorubicin, daily prednisolone for 4 weeks and daily i.v. infusion of asparaginase for 21 days. This was followed by a 4-week early consolidation (protocol IB) that included daily 6-mercaptopurine for 28 days and cytarabine for 4 consecutive days each week. The dose of drugs was identical to those used in trial 58881 (Table 1 ) except for asparaginase, admistered at 5000 IU/m 2 /day. Patients with standard risk ALL were randomized to receive or not cyclophosphamide (1 g/m 2 on days 1 and 29 of protocol IB). All medium and high risk children received this alkylating agent. After completion of IB, the interval therapy was applied consisting of an 8-week course of 6-mercaptopurine p.o. and four administrations of high-dose methotrexate injections, 500 mg/m 2 for standard risk patients and 2500 mg/m 2 for medium and high risk patients. Finally, standard risk patients (protocol 58831) received a 1 month late intensification treatment that included dexamethasone for 14 days, two doses of adriamycin and vincristine and four doses of asparaginase followed by cytarabine (two cycles as in consolidation) and 6-thioguanine. For medium and high risk patients (trial 58832) this late intensification lasted 6 instead of four weeks (protocol IIA and IIB) and was the same as trial 58881 (Table 1) . For standard risk patients, a total of six IT methotrexate injections were scheduled during these phases of treatment and, for median and high risk patients, seven IT injections. Maintenance therapy was pursued with 6-mercaptopurine daily and oral methotrexate weekly, without IT treatment, for a duration of 2 years from the start of induction therapy. Medium and high risk patients were randomized into two groups, for receiving or not prophylactic cranial radiation after the completion of protocol II and before the start of maintenance therapy. Children above 2 years of age received 24 Gy, the dose was reduced for younger patients (20 Gy between 1 and 2 years of age). Patients with CNS manifestations at diagnosis were not eligible in trial 58831/58832. The subsequent trial 58881 (1989-1998), had many similarities with trial ALL-BFM 90 (Table 1) . 9 All patients received the same induction regimen. After completion of this treatment, patients who had more than 1000 blasts/mm 3 of blood at the end of the first week of prednisolone treatment, those who did not achieve complete remission, and those with a t(4;11) or t(9;22) translocation were considered to have a very high risk of relapse and so were classed in a very high risk (VHR) group. The remaining patients considered as standard risk of relapse (low and intermediate risk) received the same treatment with a consolidation (protocol IB), an interval therapy and a protocol II (Table 1) . A total of 10 IT methotrexate injections were scheduled during the intensive phases of treatment, but no IT was planned during maintenance. Cranial radiation was systematically omitted even for patients with CNS manifestations at diagnosis (Ͼ5 blasts/mm 3 in CSF: CNS-3 status). The latter patients received two additional IT injections during induction and two during consolidation, and one IT injection, combined with high-dose methotrexate, every 3 months, during maintenance. So, patients with CNS involvement at diagnosis received a total of 20 IT methotrexate injections. The presence of CNS blast cells with fewer than five leukocytes per microliter was considered as surreptitious (CNS-2 status). In case of traumatic spinal tap with blood admixture and the impossibility of deciding between blood contamination and probable involvement, it was considered as dubious. Further to the publication of the prognostic significance of low leukemic cells in the CNS, 10 almost 40% of study population with surreptitious or dubious CNS involvement were treated the same as those with overt CNS involvement.
VHR patients received an intensified treatment for 1 year (Table 2) consisting of an intensified consolidation IB′, a 'VANDA' course, an interval therapy followed by two series of three chemotherapeutic courses (R1, R2, R3) according to the BFM relapse protocol 11 which relied on rotational highdose pulses of chemotherapy. This VHR treatment contained alkylating agents (cyclophosphamide in consolidation and ifosfamide in R2 bloc). The cumulative anthracycline dose/m 2 was 220 mg daunorubicin and 16 mg mitoxantrone. The CNSdirected chemotherapy included a total of 16 IT methotrexate injections, six of which were triple, with cytarabine and steroids, scheduled during this first year of intensified treatment See Materials and methods for definition of VHR criteria. These patients were so defined either at the end of prephase (poor responders) or during phase IA (cytogenetics) or at completion of IA (no CR). They have all received phase IA (see Table 1 ).
and also 10 courses of high-dose methotrexate. For those with CNS leukemia at diagnosis, IT methotrexate was pursued during maintenance every 3 months (a total of 20 IT injections was given during the overall treatment). Cranial radiotherapy was not planned. Maintenance therapy, initiated 2 weeks after protocol II or after the last R3 bloc, consisted of daily oral mercaptopurine (initial dose 50 mg/m 2 ) adjusted to maintain the leukocytes between 2000 and 3000/mm 3 and methotrexate 20 mg/m 2 once a week. For all patients the total duration of treatment was 2 years. This protocol was designed to test three randomized questions. Firstly, the toxicity and the efficacy of two types of asparaginase, E. coli (standard arm) and Erwinia (experimental arm), were compared when administered at equal dosage. All patients were randomized at diagnosis to participate in this comparison which was carried out between November 1990 and October 1993. The second question investigated the value of high doses of cytarabine (1 g/m 2 , twice, at a 12 h interval) combined with high doses of methotrexate during the interval therapy. Only patients with no VHR feature, either with B cell phenotype and a RF Ͼ0.8, or those with T cell lineage were eligible for this second randomisation, which was carried out between September 1989 and January 1996. The third randomization was made to test the advantage of adding monthly intravenous 6-mercaptopurine (1 g/m 2 ) to conventional maintenance therapy. All patients in complete remission after protocol II or after the last R3 bloc for those qualified as VHR, were eligible for this third question, which included patients between November 1990 and November 1996.
Diagnostic procedure
Diagnosis based on morphologic, biochemical and immunologic features of leukemic cells was done locally. Cytology was centrally reviewed (A-M Manel). Immunophenotype was determined according to reactivity to a panel of monoclonal antibodies. As the requirements for immunologic studies were completely revised during the study period 1983/89, too few patients could be evaluated after immunological centralized review for trial 58831/32. For karyotyping of leukemic cells, banded chromosomes were prepared from 24-h cultured preparations and aberrations were designated according to the International System for Cytogenetic Nomenclature. The karyotypes of all patients done locally were centrally reviewed (N Dastugue). Molecular analyses as the detection of t(12;21) or t(9;22) translocations carried out by FISH or RT-PCR or the study of minimal residual disease were performed in reference laboratories and reviewed by H Cavé and C Preudhomme.
Statistical analysis
The EFS was calculated from the date of CR until the date of first relapse or until death in CR; patients who did not reach CR either after the induction IA or the consolidation IB or IB′ were considered as events at time 0. In patients who reached CR, the disease-free survival (DFS) was defined as EFS. The CNS relapse-free interval was defined as DFS, except that patients were censored at the time of extra-CNS relapse or at the date of death, if one of these occurred. An isolated CNS relapse was defined as one without simultaneous relapse at another site. CNS relapses included CNS relapses isolated or combined with another type of relapse. For randomized patients, all of the previously defined durations were calculated from the date of randomization. The actuarial curves were computed using the Kaplan-Meier technique, 12 and the standard errors (s.e.) of the estimates were obtained via the Greenwood formula. 12 The differences between curves were tested for statistical significance using the two-tailed log rank test. 12 In order to summarize the overall treatment difference the hazard ratio (HR) of having an event per time unit in one arm vs the other, along with its 95% confidence interval, were estimated using the odds-ratio technique. 13 All analyses were performed on the basis of 'intent-to-treat'; only patients who remained failure-free were censored on the date of last contact. For 2 × 2 contingency tables, the Fisher test was used. The databases for the three studies were 'frozen' in November 1999.
Results
Seven hundred and eighty ALL patients were registered in study 58831/58832. Among them, 735 were eligible for evaluation of the induction response, whereas 45 were considered as ineligible: seven had a CNS involvement and two suspicious CNS involvement (in addition to other ineligibility features), 31 had other features which precluded inclusion in the trial, two patients had an unknown RF and three were eligible, but the response to treatment was not evaluable. Of 735 eligible and evaluable patients, 11 were considered à posteriori by the study coordinator as having CNS involvement, and eight as dubious or surreptitious involvement. However, they have been been included by the local investigators in the study 58831 or 58832, and therefore included in the analyses, in order to comply with the intent-to-treat principle. A total of 707 (96.2%) patients achieved complete remission after induction. The overall EFS rate (±1 s.e.) was 66% ± 1.8% at 6 years, 65% ± 1.8% at 8 and 10 years ( Figure  1 ). The actuarial risk of CNS relapse rates at 6 and 10 years was 11% ± 1.2% and 12% ± 1.3% ( Figure 1) ; the corresponding isolated CNS relapse rates were 6% ± 1% and 7% ± 1%, respectively. The different causes of events are detailed in Table 3 . The estimated survival rates were 79% ± 1.5% at 6 years and 78% ± 1.5% at 8 years. The median follow-up duration was 9.4 years. A total of 383 standard risk patients were randomized into two groups, to receive or not cyclophosphamide during IB. The two groups were well balanced regarding several initial features. Absence of cyclophosphamide had no impact on outcome as DFS rates ±1 s.e. at 10 years were respectively 71% ± 3.3% and 70% ± 3.7% with and without cyclophosphamide (Figure 2 ). The estimated hazard ratio (No CPM vs CPM: control group) was 1.06, and the 95% CI was 0.72-1.56, which indicates that the loss in the therapeutic activity by deleting CPM is almost significantly lower than 10%, as a loss in DFS at 10 years from 75% to 65% corresponds to an HR = 1.50. For medium and high risk patients, a total of 183 patients were randomized into two groups, to receive high-dose methotrexate alone or high-dose methotrexate followed by cranial radiotherapy. High-dose methotrexate alone was as effective as high-dose methotrexate followed by cranial radiotherapy in terms of DFS, isolated CNS relapse-free interval and CNS relapse-free interval ( Figure  3 ). The 6-year DFS rates were respectively 66% ± 5.0% and 68% ± 4.8%, the isolated CNS relapse rates were respectively 7% ± 2.9% and 7% ± 2.8% and the CNS relapse rates were
Figure 1
Event-free survival and CNS relapse-free interval in patients enrolled in trial 58831/32. N, number of patients at risk; O, observed number of events. 
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Figure 2
Comparison of disease-free survival in patients randomly assigned to receive or not cyclophosphamide (CPM) in trial 58831. N, number of patients at risk; O, observed number of events.
Figure 3
Comparison of disease-free survival and CNS relapse-free interval in medium and high risk patients randomly assigned to receive or not cranial radiotherapy in trial 58832. N, number of patients at risk; O, observed number of events.
respectively 15% ± 4.0% and 9% ± 3.2% with or without cranial irradiation. The estimated hazard ratio (no radio vs radio: control group) was 0.57, its 95% CI was 0.24-1.35, which indicates that by deleting radiotherapy the increase in the CNS relapse is significantly lower than 10%, as an increase in CNS relapse rate at 10 years from 10% to 20% corresponds to an HR = 2.12.
For trial 58881, 2078 ALL patients were enrolled, of whom 13 could not be evaluated due to lack of information, protocol violation, treatment refusal, etc. Of the remaining 2065 patients, 2019 (97.8%) achieved complete remission, 27 were resistant, nine died during the induction phase and 10 died before the start of induction. The overall EFS rate was 70.9% ± 1.1% at 5 years and 68.4% ± 1.2% at 8 years ( Figure 4) . The actuarial median follow-up duration was 5 years. The 5-and 8-year cumulative incidence rates of isolated CNS relapse were 4% ± 0.5% and 4.2% ± 0.5%, respectively, and that of overall relapse were 7.7% ± 0.7% and 8.3% ± 0.7%, respectively ( Figure 4) . The different causes of events are detailed in Table 3 . The estimated survival rate was 82% ± 0.9% at 5 years and 79% ± 1% at 8 years. A total of 653 ALL children were randomized to receive E. coli asparaginase or Erwinia
Figure 4
Event-free survival and probability of isolated or overall CNS relapse in all patients enrolled in trial 58881. N, number of patients at risk, O, observed number of events.
asparaginase. Coagulation abnormalities were more frequent in the E coli asparaginase-treated group than in the Erwinia asparaginase-treated group. The induction failure rate was higher in the Erwiniase group (3.8%) than in the E coli group (1.2%), the estimated odds ratio was 3.23, the exact 95% confidence interval was 0.96-13.84, and the Fisher exact test yielded a P = 0.04. The median (minimum, maximum) followup was 6.9 (4, 10) years. The estimated EFS rates at 5 years were 74.0% ± 2.4% in the E. coli group vs 61.1% ± 2.7% in the Erwiniase group (logrank P = 0.0006), with a lower 5-year relapse rate (23.6% vs 35.0%) in the E. coli group. Estimated survival rates at 5 years were 83.2% ± 2.0% in the E. coli group vs 76.8% ± 2.4% in the Erwiniase group.
A total of 593 patients were randomized to two groups to test the value of cytarabine in interval therapy. The median follow-up was 6 years. The 5-year disease-free survival rates were similar in both groups: 71.3% ± 2.7% vs 71.4% ± 2.6%, respectively, without and with cytarabine. The 5-year incidence of CNS relapse rates were similar; isolated (6.5% ± 1.5% vs 3.7% ± 1.1%, respectively, without and with cytarabine) or overall (12.9% ± 2.1% vs 9.7% ± 1.7%). The 5-year survival rates were practically identical, at 85.5%, in the two treatment groups. A total of 820 patients were randomized to two groups for maintenance therapy without or with i.v. 6-mercaptopurine. The median follow-up was 5.3 years. The prognostic factors and the type of asparaginase previously received were well balanced between the two treatment groups. The DFS rate at 5 years was lower in the arm receiving i.v. 6-mercaptopurine: 71.2% ± 2.3% vs 78.6% ± 2.1% (logrank P = 0.027). Considering only the patients who had been randomized to receive the less potent asparaginase, the difference between the two maintenance groups was more marked (59.2% ± 4.8% vs 74.5% ± 4.3%; HR = 1.71) than in those patients who had been randomized to receive E. coli asparaginase (78.2% ± 3.9% vs 78.4% ± 3.9%; HR = 1.08). The type of interaction was partly explained by an imbalance of prognostic factors (boys vs girls) in treatment groups. Conversely the difference between the two asparaginase groups was greater in the group having received intravenous 6-mercaptopurine.
Relation between early treatment response and prognosis
It was confirmed that poor response to the prephase (у1000 blasts/mm 3 at day 8 of steroid prephase) was associated with a less favorable EFS (5-year EFS at 55% in trial 58881). Possible factors contributing to this poor response to prephase were investigated in 1044 patients. 14 The day of IT methotrexate administration during prephase had a significant influence on the frequency of good responders. When IT was administered before day 2, 90% of patients were good responders compared to 77% and 70%, respectively, when IT was given between days 2 and 6 and after day 6. Immunophenotype was also an important predictor of response to prephase treatment (56% in T-ALL) and the influence of the day of IT methotrexate could not be detected in T-ALL.
The predictive value of the measurements of residual disease at several early time points during the first 6 months after complete remission was determined by quantitating residual blasts in the marrow with a competitive PCR assay. 15 Junctional sequences of T cell receptor or immunoglobulin gene rearrangements were used as clonal markers. The detection and the level of residual leukemia were significantly correlated with the risk of early relapse for the series of 178 patients monitored for residual disease during a median follow-up period of 38 months. We herein provide an update of this study with a median follow-up of more than 5 years. As shown in Figure 5a and b, the relapse-free interval according to the detection and level of residual disease after the completion of induction remained roughly the same for a threshold highly predictive of relapse at 10 −2 . Similar results were observed at further time points: after consolidation, interval therapy, and protocol II for a critical level of residual disease at 10 −3 (data not shown). Furthermore it is confirmed that some late relapses were reported in patients from whom the residual disease was at a low or undetectable level at different timepoints.
Treatment results according to prognostic factors
In study 58831/32, the distribution of prognostic factors such as age, sex, leukemic burden measured by leukocyte counts or RF was similar to that reported in other cohorts ( Table 4) . The factors associated with a better prognosis included age 2 to 5 years and a RF Ͻ0.8 (Table 4 ). In study 58881 the prognostic impact of presenting clinical and biological features are given in Table 5 . The predictive strength of NCI/Rome criteria in B lineage ALL was confirmed, as well as the impact of response to steroid prephase. The overall EFS rate in 60 infants No immunophenotype data were available for this study.
treated with the same protocol was 39% at 8 years and the impact of different prognostic factors was studied in this series by univariate analysis. 16 Late relapses in patients with translocation t(12;21) affected their ultimate outcome. This was probably the consequence of intravenous 6-mercaptopurine randomization in this subset of patients: the 6-year EFS was estimated at 100% for those randomized to receive conventional maintenance compared to 57% for those randomized to receive additional i.v. 6-mercaptopurine. Immunophenotype had a moderate influence although statistically significant, on the prognosis evaluated in terms of EFS ( Figure 6 ). The cumulative incidence of CNS relapse at 8 years according to presenting features is shown in Table 6 . Adverse factors included B lineage with a WBC of at least 100 × 10 9 /l, T cell immunophenotype. The impact of CNS status at diagnosis was moderate in case of overt involvement but more important in case of CNS-2 status. In addition the isolated CNS rate was as follows: for B-lineage, 3.2% and 7.3%, respectively, according to whether WBC was Ͻ or у100 × 10 9 /l, and for T lineage, 9.4% and 8.1%, respectively, according to whether WBC was Ͻ or у100 × 10 9 /l.
Discussion
The analysis of long-term follow-up in patients treated in consecutive trials showed an expected occurrence of late relapse at between 1% and 2.5% for the overall series of patients followed-up for 8 to 10 years. Risk classification based on leukocyte counts remained highly significant whatever the age. 16 As our trials presented some similarities with the BFM 86 and 90 trials it is interesting to compare the type and the frequency of events and the prognostic impact of initial features. 9, 17 In Leukemia trial 58881 patients with classical favorable variables (RF Ͻ0.8, good risk by NCI criteria, t(12;21), hyperdiploidy) did not fare as well as expected. This is probably the consequence of worse treatment results in groups randomized to receive Erwinia asparaginase or intravenous 6-mercaptopurine. Erwiniase randomization had a more pronounced negative impact in patients with hyperdiploidy (data not shown) and intravenous 6-mercaptopurine affected the ultimate outcome of patients with t(12;21). No early or late relapse was observed in patients with t(12;21) receiving conventional maintenance and the 5-year EFS was estimated at 90% in hyperdiploid patients receiving the more potent asparaginase. Poor prednisolone responders who comprised 12% of the study population were included in the VHR group intensively treated over 1 year. Although the treatment outcome remained unsatisfactory and the treatment intensity questionable, our VHR results were encouraging (5-year EFS rate at 48.1%). The contribution of transplantation to the treatment results was small, except for the mortality rate in CR, since 25.8% of VHR patients who reached CR and having undergone transplantation did not fare better. The intensified consolidation (phase IB′) which encompassed high-dose methotrexate and cytarabine, the VANDA course which incorporated mitoxantrone and etoposide and the two series of three rotational pulses of drugs might improve the prognosis. Immunophenotype had a moderate impact on the ultimate EFS. Patients with T-ALL maintained an EFS at 62% at 8 years, the NCI/Rome criteria being inadequate for classification of these patients.
As expected with a prolonged follow-up, the predictive value of minimal residual disease, although remaining similar, was somewhat less important since late relapses may occur in patients with low or undetectable levels of residual leukemia after the completion of the induction regimen. In this respect it is well confirmed that the measurement of residual disease early on in the first 6 months of complete remission is a relevant parameter to predict early but not late relapses. Hence, strategies for decreased chemotherapy in a low risk residual disease group should be applied with caution and take into account this risk of late relapse.
Further to these data, the CLCG decided in the current trial (58951) not to randomize the treatment intensity according to the level of residual disease, but to use a semi-quantitative detection of residual disease in clinical practice. The aim is to identify 10% of patients with high level of residual disease (у10 −2 ) and thus with a high risk of early relapse. The fluorescence PCR analysis of gene rearrangements, set up in several reference laboratories can be performed rapidly with sensitivity at 5 × 10 −3 allowing us subsequently to tailor the treatment. 18 The patients classified as being at high risk are offered the option of allogeneic stem cell transplantation.
One of the goals of CLCG trials was to prevent the recurrence of CNS manifestations by addressing several randomized questions: the role of CNS radiotherapy in trial 58832 and the potential benefit of CNS directed therapy in study 58881. In the groups of intermediate and high risk patients treated with high-dose methotrexate and six IT injections of methotrexate, radiotherapy did not influence the risk of CNS relapse or the treatment outcome. Consequently, radiotherapy was always omitted even in patients considered at high risk of CNS relapse in trial 58881. This strategy was justified by the long-term toxicity of radiotherapy with about 3% expected secondary tumors. 19 Furthermore radiotherapy may cause neurocognitive deficits and may render any attempt at salvage therapy more difficult. Radiotherapy was replaced by more intensive IT treatment and high-dose metho- 
Figure 6
Event-free survival and probability of CNS relapse according to the immunophenotype: B lineage or T lineage ALL in patients enrolled in trial 58881. N, number of patients at risk; O, observed number of events. trexate in 83% of patients enrolled in this trial, considered at standard risk. Patients in the VHR group, which included the majority of patients at high risk of CNS relapse and 40% of the T lineage group, were intensively treated by IT and several courses of high-dose cytarabine and methotrexate. The relapse rate confined to the CNS in the overall series of patients as well as in subgroups at higher risk of CNS relapse are less satisfying than that published by other groups including the radiotherapy in treatment protocols. 9, 20 Nevertheless it might be considered as acceptable by comparison with the expected risk of secondary malignancies following radiotherapy and the complexity of salvage therapy in irradiated patients. The early and intensive IT treatment combined with systemic chemotherapy was effective in patients with CNS leukemia at diagLeukemia nosis. As only 40% of patients with surreptitious involvement benefited from intensified IT treatment, the incidence of CNS relapse was higher in this subgroup. In T-ALL the omission of radiotherapy did not jeopardize the cure rate even in patients with WBC of at least 100 × 10 9 /l in contrast with another report. 21 However, the incidence of any CNS relapse (combined and isolated) remained too high (Table 6 ) in our different categories of patients compared to recent publications. Radiotherapy may have a systemic effect or contribute to prevent the spreading of leukemic cells between CNS and marrow. Thus the question remains open as to whether radiotherapy could be desirable for a small subgroup of patients.
Several questions and comments have raised concerning the randomized questions addressed in these studies. The results of trial 58831 showing that cyclophosphamide omission did not increase the risk of early or late relapse in low risk patients prompted us to omit this agent from our ongoing study (58951) for the low risk group. High-dose cytarabine when combined with methotrexate in interval therapy failed to improve the outcome and the risk of CNS relapse in trial 58881. This result should be interpreted in the light of pharmacological data showing that cytarabine alters methotrexate pharmacology when the drugs are infused together. 22 The deleterious effect of i.v. 6-mercaptopurine added during maintenance therapy remains unexplained. The dose intensity in oral 6-mercaptopurine for some patients receiving the i.v. drug might play a role, 23 or methotrexate might interfere with the metabolism of 6-mercaptopurine given orally and intravenously. The group receiving E. coli asparaginase showed better results in terms of CR rate, EFS and survival compared to the group receiving Erwinia asparaginase. These differences, not expected when the trial was designed, could be explained by recent pharmacological data. The serum half life of E. coli asparaginase and the in vivo asparagine depletion induced by E. coli are significantly longer than that of Erwinia asparaginase. 24, 25 Our data underline the importance of optimal asparaginase treatment in ALL trials and prompted us to investigate the benefit of prolonged asparaginase treatment in our current trial (58951). E. coli asparaginase is used in this study and, in case of toxicity to this drug, the switch to Erwinia asparaginase (at higher doses) is recommended.
The main conclusion that can be drawn from the above results is the requirement of pharmacogenetic and pharmacokinetic studies to be performed before designing randomized phase III trials in ALL children.
